Symbols

CHRS

Coherus Oncology·NASDAQ

--(--)

CHRS fundamentals

CHRS Q4 2025 Earnings

Coherus Oncology (CHRS) released its earnings on Mar 9, 2026: revenue was 12.75M (YoY -76.46%), missed estimates; EPS was -0.39 (YoY +11.36%), missed estimates.

Revenue / YoY

12.75M

-76.46%

EPS / YoY

-0.39

+11.36%

Report date

Mar 9, 2026

CHRS Earnings Call Summary for Q4,2025

Revenue Surge: LOQTORZI net revenue up 113% YoY to $40.8M in 2025, with Q4 demand growth of 15.5%.
Pipeline Momentum: Tagmokitug and Casdozokitug trials across 8 tumor types, with first data mid-2026. J&J collaboration for prostate cancer combo.
Financial Strength: $172M cash, 90% debt reduction, and 20% SG&A expense decline. Eligible for $75M in UDENYCA earn-outs.
Strategic Expansion: Field force +15%, CRM tech doubling claims data coverage, targeting 65% of U.S. patients.

Earnings

EPS

Revenue

Revenue & Expenses

CHRS has released its 2025 Q4 earnings report, with revenue of 12.75M, reflecting a YoY change of 64.85%, and net profit of -37.64M, showing a YoY change of 25.75%. The Sankey diagram below clearly presents CHRS's revenue sources and cost distribution.

Key Indicators

Coherus Oncology (CHRS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Coherus Oncology (CHRS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Coherus Oncology (CHRS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Coherus Oncology (CHRS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown